Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) Director Young-Jin Kim purchased 1,230,769 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $3,999,999.25. Following the transaction, the director now owns 8,423,386 shares in the company, valued at $27,376,004.50. This represents a 17.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Rezolute Trading Down 0.5%

RZLT traded down $0.02 during trading on Thursday, reaching $4.31. The stock had a trading volume of 803,717 shares, compared to its average volume of 588,785. The company has a market capitalization of $368.59 million, a price-to-earnings ratio of -3.75 and a beta of 1.04. The stock's 50 day moving average is $3.92 and its two-hundred day moving average is $4.09. Rezolute, Inc. has a one year low of $2.22 and a one year high of $6.19.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, equities research analysts predict that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on RZLT shares. Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a report on Wednesday, May 14th. Wall Street Zen lowered shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price target on shares of Rezolute in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Rezolute has an average rating of "Moderate Buy" and an average target price of $11.83.

Institutional Trading of Rezolute

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RZLT. Jeppson Wealth Management LLC bought a new position in shares of Rezolute in the first quarter worth approximately $35,000. Paloma Partners Management Co purchased a new position in shares of Rezolute in the first quarter worth $48,000. Alpine Global Management LLC bought a new position in shares of Rezolute during the fourth quarter worth $54,000. XTX Topco Ltd bought a new position in shares of Rezolute during the first quarter worth $95,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its position in shares of Rezolute by 48.5% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after purchasing an additional 6,470 shares in the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.